Ontology highlight
ABSTRACT:
SUBMITTER: Eser PO
PROVIDER: S-EPMC8627689 | biostudies-literature | 2021 Sep
REPOSITORIES: biostudies-literature
Eser Pınar Özden PÖ Paranal Raymond M RM Son Jieun J Ivanova Elena E Kuang Yanan Y Haikala Heidi M HM To Ciric C Okoro Jeffrey J JJ Dholakia Kshiti H KH Choi Jihyun J Eum Yoonji Y Ogino Atsuko A Missios Pavlos P Ercan Dalia D Xu Man M Poitras Michael J MJ Wang Stephen S Ngo Kenneth K Dills Michael M Yanagita Masahiko M Lopez Timothy T Lin Mika M Tsai Jeanelle J Floch Nicolas N Chambers Emily S ES Heng Jennifer J Anjum Rana R Santucci Alison D AD Michael Kesi K Schuller Alwin G AG Cross Darren D Smith Paul D PD Oxnard Geoffrey R GR Barbie David A DA Sholl Lynette M LM Bahcall Magda M Palakurthi Sangeetha S Gokhale Prafulla C PC Paweletz Cloud P CP Daley George Q GQ Jänne Pasi A PA
Science translational medicine 20210901 609
The clinical efficacy of epidermal growth factor receptor (EGFR)–targeted therapy in <i>EGFR</i>-mutant non–small cell lung cancer is limited by the development of drug resistance. One mechanism of EGFR inhibitor resistance occurs through amplification of the human growth factor receptor (<i>MET</i>) proto-oncogene, which bypasses EGFR to reactivate downstream signaling. Tumors exhibiting concurrent <i>EGFR</i> mutation and <i>MET</i> amplification are historically thought to be codependent on t ...[more]